0001437749-25-004911.txt : 20250224 0001437749-25-004911.hdr.sgml : 20250224 20250224171600 ACCESSION NUMBER: 0001437749-25-004911 CONFORMED SUBMISSION TYPE: RW PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250224 DATE AS OF CHANGE: 20250224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moleculin Biotech, Inc. CENTRAL INDEX KEY: 0001659617 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474671997 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: RW SEC ACT: SEC FILE NUMBER: 333-283820 FILM NUMBER: 25658189 BUSINESS ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 BUSINESS PHONE: 713-300-5160 MAIL ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 RW 1 mbrx20250224_rw.htm FORM RW mbrx20250224_rw.htm

Moleculin Biotech, Inc.

5300 Memorial Drive, Suite 950

Houston, TX 77007

 

 

February 24, 2025

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

 

 

Re:

Moleculin Biotech, Inc.

Registration Statement on Form S-1

Registration No. 333-283820 (“Registration Statement”)

 

Ladies and Gentlemen:

 

Please be advised that the Company hereby requests withdrawal of the above-referenced Registration Statement pursuant to Rules 477 and 478 of Regulation C promulgated by the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”). The Registration Statement was originally filed on December 13, 2024 and has not been declared effective. The Company has determined not to proceed with the planned offering and confirms that no securities were sold in connection with the offering. Accordingly, the Company hereby requests withdrawal of the Registration Statement as of the date hereof or at the earliest practicable date hereafter.

 

The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, the Company respectfully requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration statement or registration statements.

 

  Very truly yours,  
     
  Moleculin Biotech, Inc.  

 

 

 

 

 

 

 

 

 

 

 

 

By:

/s/ Jonathan P. Foster

 

 

 

  Name: Jonathan P. Foster

 

 

 

  Title: Chief Financial Officer